Suppr超能文献

腺相关病毒血清型的包装能力:更大基因组对感染性及进入后步骤的影响

Packaging capacity of adeno-associated virus serotypes: impact of larger genomes on infectivity and postentry steps.

作者信息

Grieger Joshua C, Samulski Richard J

机构信息

Curriculm in Genetics and Molecular Biology and Gene Therapy Center, University of North Carolina at Chapel Hill, 27599-7352, USA.

出版信息

J Virol. 2005 Aug;79(15):9933-44. doi: 10.1128/JVI.79.15.9933-9944.2005.

Abstract

The limited packaging capacity of adeno-associated virus (AAV) precludes the design of vectors for the treatment of diseases associated with larger genes. Autonomous parvoviruses, such as minute virus of mice and B19, while identical in size (25 nm), are known to package larger genomes of 5.1 and 5.6 kb, respectively, compared to AAV genomes of 4.7 kb. One primary difference is the fact that wild-type (wt) AAV utilizes three capsid subunits instead of two to form the virion shell. In this study, we have characterized the packaging capacity of AAV serotypes 1 through 5 with and without the Vp2 subunit. Using reporter transgene cassettes that range in size from 4.4 to 6.0 kb, we determined that serotypes 1 through 5 with and without Vp2 could successfully package, replicate in, and transduce cells. Dot blot analysis established that packaging efficiency was similar for all vector cassettes and that the integrity of encapsidated genomes was intact regardless of size. Although physical characterization determined that virion structures were indistinguishable from wt, transduction experiments determined that all serotype vectors carrying larger genomes (5.3 kb and higher) transduced cells less efficiently (within a log) than AAV encapsidating wt size genomes. This result was not unique to reporter genes and was observed for CFTR vector cassettes ranging in size from 5.1 to 5.9 kb. No apparent advantage in packaging efficiency was observed when Vp2 was present or absent from the virion. Further analysis determined that a postentry step was responsible for the block in infection and specific treatment of cells upon infection with proteasome inhibitors increased transduction of AAV encapsidating larger DNA templates to wt levels, suggesting a preferential degradation of virions encapsidating larger-than-wt genomes. This study illustrates that AAV is capable of packaging and protecting recombinant genomes as large as 6.0 kb but the larger genome-containing virions are preferentially degraded by the proteasome and that this block can be overcome by the addition of proteasome inhibitors.

摘要

腺相关病毒(AAV)有限的包装能力限制了用于治疗与较大基因相关疾病的载体设计。自主细小病毒,如小鼠微小病毒和B19,虽然大小相同(25纳米),但已知它们分别能包装5.1和5.6千碱基的更大基因组,而AAV基因组为4.7千碱基。一个主要区别是野生型(wt)AAV利用三个衣壳亚基而非两个来形成病毒粒子外壳。在本研究中,我们对有无Vp2亚基的1至5型AAV血清型的包装能力进行了表征。使用大小从4.4至6.0千碱基的报告转基因盒,我们确定有无Vp2的1至5型血清型都能成功包装、在细胞中复制并转导细胞。斑点印迹分析表明,所有载体盒的包装效率相似,且无论大小,衣壳化基因组的完整性均保持完好。尽管物理表征确定病毒粒子结构与野生型无异,但转导实验表明,所有携带较大基因组(5.3千碱基及以上)的血清型载体转导细胞的效率(相差一个对数级)低于包装野生型大小基因组的AAV。这一结果并非报告基因所特有,在大小从5.1至5.9千碱基的CFTR载体盒中也观察到了。病毒粒子中有无Vp2时,在包装效率上未观察到明显优势。进一步分析确定,感染后的一个步骤导致了感染受阻,用蛋白酶体抑制剂处理细胞后,包装较大DNA模板的AAV的转导增加至野生型水平,这表明衣壳化大于野生型基因组的病毒粒子被优先降解。本研究表明,AAV能够包装和保护长达6.0千碱基的重组基因组,但含有较大基因组的病毒粒子会被蛋白酶体优先降解,且添加蛋白酶体抑制剂可克服这一障碍。

相似文献

2
Quantitative analysis of the packaging capacity of recombinant adeno-associated virus.
Hum Gene Ther. 1996 Nov 10;7(17):2101-12. doi: 10.1089/hum.1996.7.17-2101.
3
Improved Genome Packaging Efficiency of Adeno-associated Virus Vectors Using Rep Hybrids.
J Virol. 2021 Sep 9;95(19):e0077321. doi: 10.1128/JVI.00773-21. Epub 2021 Jul 21.
5
Effect of genome size on AAV vector packaging.
Mol Ther. 2010 Jan;18(1):80-6. doi: 10.1038/mt.2009.255. Epub 2009 Nov 10.
7
Expressing Transgenes That Exceed the Packaging Capacity of Adeno-Associated Virus Capsids.
Hum Gene Ther Methods. 2016 Feb;27(1):1-12. doi: 10.1089/hgtb.2015.140.

引用本文的文献

1
Generation and evaluation of a novel PI3K-targeting gene therapy in the failing mouse heart and healthy sheep heart.
J Mol Cell Cardiol Plus. 2025 Jul 31;13:100478. doi: 10.1016/j.jmccpl.2025.100478. eCollection 2025 Sep.
2
An Alternative Gene Editing Strategy Using a Single AAV Vector.
Bio Protoc. 2025 Jul 5;15(13):e5362. doi: 10.21769/BioProtoc.5362.
3
Exploring AAV-Mediated Gene Therapy for Inner Ear Diseases: from Preclinical Success to Clinical Potential.
Adv Sci (Weinh). 2025 Sep;12(33):e08397. doi: 10.1002/advs.202408397. Epub 2025 Jun 20.
4
Revolution of AAV in Drug Discovery: From Delivery System to Clinical Application.
J Med Virol. 2025 Jun;97(6):e70447. doi: 10.1002/jmv.70447.
6
Treatment of a metabolic liver disease in mice with a transient prime editing approach.
Nat Biomed Eng. 2025 May 20. doi: 10.1038/s41551-025-01399-4.
7
Current trends in gene therapy to treat inherited disorders of the brain.
Mol Ther. 2025 May 7;33(5):1988-2014. doi: 10.1016/j.ymthe.2025.03.057. Epub 2025 Apr 2.
8
SunTag-PE: a modular prime editing system enables versatile and efficient genome editing.
Commun Biol. 2025 Mar 18;8(1):452. doi: 10.1038/s42003-025-07893-4.
9
Use of an oversized AAV8 vector for CPS1 deficiency results in long-term survival and ammonia control.
Mol Ther Nucleic Acids. 2025 Feb 3;36(1):102470. doi: 10.1016/j.omtn.2025.102470. eCollection 2025 Mar 11.
10
Mesenchymal Stem Cells Expressing Baculovirus-Engineered Brain-Derived Neurotrophic Factor Improve Peripheral Nerve Regeneration in a Rat Model.
Tissue Eng Regen Med. 2025 Apr;22(3):351-362. doi: 10.1007/s13770-025-00703-2. Epub 2025 Feb 17.

本文引用的文献

1
Production of recombinant adeno-associated viral vectors.
Curr Protoc Hum Genet. 2007 Apr;Chapter 12:Unit 12.9. doi: 10.1002/0471142905.hg1209s53.
2
Hepatocyte growth factor receptor is a coreceptor for adeno-associated virus type 2 infection.
J Virol. 2005 Jan;79(1):609-14. doi: 10.1128/JVI.79.1.609-614.2005.
3
Integration of adeno-associated virus (AAV) and recombinant AAV vectors.
Annu Rev Genet. 2004;38:819-45. doi: 10.1146/annurev.genet.37.110801.143717.
6
Structure of adeno-associated virus serotype 5.
J Virol. 2004 Apr;78(7):3361-71. doi: 10.1128/jvi.78.7.3361-3371.2004.
8
Role of interfacial amino acid residues in assembly, stability, and conformation of a spherical virus capsid.
Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2724-9. doi: 10.1073/pnas.0307748101. Epub 2004 Feb 23.
9
In vitro disassembly of a parvovirus capsid and effect on capsid stability of heterologous peptide insertions in surface loops.
J Biol Chem. 2004 Feb 20;279(8):6517-25. doi: 10.1074/jbc.M307662200. Epub 2003 Dec 1.
10
Release of canine parvovirus from endocytic vesicles.
Virology. 2003 Nov 25;316(2):267-80. doi: 10.1016/j.virol.2003.08.031.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验